New peer-reviewed publication

ImmuPharma reports new preclinical data for P140 in MASH, but only in mice.

What the company is saying

ImmuPharma PLC (LSE:IMM, AIM:IMM) is highlighting the publication of new peer-reviewed research on its P140 peptide in a preclinical mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The company frames this as evidence of P140’s biological activity beyond its original lupus indication, emphasizing that the treatment reduced steatohepatitis and fibrosis and improved several disease-related parameters in mice. The announcement quotes Professor Sylviane Muller, co-inventor of P140, and CEO Tim McCarthy, both stressing the importance and breadth of the findings and the intention to continue development. The release uses qualitative terms such as 'important new evidence' and 'valuable peer-reviewed evidence' to position the study as a milestone. No financial figures, clinical data, or operational milestones are disclosed, and the messaging is focused on scientific validation and pipeline potential rather than near-term commercial impact.

What the data suggests

The only hard data disclosed are bibliographic: the publication date (15 September 2026), journal (Pharmacological Research, Volume 232, article 108427), and authorship (CNRS and University of Strasbourg, including Professor Sylviane Muller). The study was conducted in an established mouse model of advanced MASH, with P140 reportedly reducing steatohepatitis and fibrosis and modifying lysosomal and autophagy-associated markers. No quantitative results, effect sizes, or statistical significance are provided. There is no mention of human data, clinical trial progress, or financial impact. The evidence supports that P140 has activity in a preclinical MASH model, but the claims about broader disease relevance and value are not substantiated by disclosed numbers.

Analysis

The announcement is positive in tone, highlighting the publication of new peer-reviewed research on P140 in a preclinical MASH model. The realised facts are limited to the publication itself and the conduct of the preclinical study in mice, with no clinical or commercial milestones achieved. Several claims, such as the 'breadth' of P140's biological activity and its potential across multiple diseases, are forward-looking and aspirational, lacking quantitative or comparative data. The language inflates the significance of the findings by implying broad applicability and value without supporting numerical evidence. No capital outlay or financial impact is disclosed, and the benefits of this research (if any) are long-term, as further preclinical and clinical development would be required before any commercial or patient impact. The gap between narrative and evidence is moderate: while the publication is a legitimate milestone for an R&D-stage biotech, the claims about broader impact and value are not substantiated by data in the release.

Risk flags

• ●The findings are limited to an animal model, which often fails to predict efficacy or safety in humans. This translational gap is a major risk for drug development and means the results may not be reproducible in clinical settings.
• ●No quantitative data or statistical results are disclosed, making it impossible to independently assess the magnitude or robustness of the reported effects. This lack of detail reduces the credibility and actionable value of the findings.
• ●There is no disclosure of clinical development timelines, regulatory milestones, or funding status for advancing P140 in MASH or other indications. This leaves execution risk high and the path to value unclear.

Bottom line

This announcement signals incremental scientific progress for ImmuPharma’s P140 peptide, with new peer-reviewed data showing activity in a mouse model of MASH. The absence of quantitative results, human data, or clinical milestones means the news is not immediately actionable for investors. The company’s narrative is aspirational, projecting broad potential for P140 without supporting numbers or a defined development path. The main takeaway is that P140 remains at an early, high-risk stage for MASH, and any commercial or clinical impact is years away. Investors should expect further preclinical or clinical updates before reassessing the asset’s value. The most important fact is that all evidence remains preclinical and unquantified.

Announcement summary

(LSE: IMM) ImmuPharma PLC announced the publication of new peer-reviewed research evaluating P140 in a preclinical model of metabolic dysfunction-associated steatohepatitis (MASH). The paper, entitled "Restoring lysosomal proteostasis reverses steatohepatitis and fibrosis in experimental MASH", was published in Pharmacological Research by researchers from CNRS and the University of Strasbourg, including Professor Sylviane Muller, co-inventor of P140. P140 was evaluated in an established mouse model of advanced MASH characterised by liver inflammation and fibrosis. Treatment with P140 reduced steatohepatitis and fibrosis and improved several disease-related histological and biological parameters. P140 selectively modified a number of dysregulated lysosomal and autophagy-associated markers, while the scrambled control peptide did not reproduce these effects. The study provides further peer-reviewed evidence of the biological activity of P140 beyond its original lupus setting and supports continued investigation across diseases characterised by dysregulated cellular homeostasis and autophagy activity. The publication is available in Pharmacological Research, Volume 232 (2026), article 108427. Professor Sylviane Muller commented that these results provide important new evidence of the biological activity of P140 in an experimental model of advanced MASH and support continued investigation of P140 across disease settings characterised by dysregulated cellular homeostasis. Tim McCarthy, Chief Executive Officer of ImmuPharma PLC, stated that the study adds valuable peer-reviewed evidence to the growing body of research around P140 and further demonstrates the breadth of its biological activity.

Disagree with this article?